Mesothelioma Clinical Trials

Clinical trials are carefully designed research studies that evaluate new treatments, treatment combinations, or treatment approaches in human volunteers. For patients with mesothelioma — a rare cancer with limited standard treatment options — clinical trials represent one of the most important pathways to accessing potentially life-extending therapies that are not yet widely available. Every treatment currently used for mesothelioma, from pemetrexed chemotherapy to nivolumab-ipilimumab immunotherapy, was proven effective through clinical trials before becoming standard of care.¹

Clinical trials follow a structured process divided into four phases. Phase I trials enroll small numbers of patients (15–30) to determine the safe dosage and identify side effects of a new treatment. Phase II trials expand enrollment (30–100+ patients) to evaluate whether the treatment shows meaningful anti-tumor activity in a specific cancer type. Phase III trials are large, randomized studies (hundreds to thousands of patients) that compare the new treatment against the current standard of care to determine if it offers superior outcomes. Phase IV trials occur after FDA approval and monitor long-term safety and effectiveness in broader patient populations.²

The mesothelioma clinical trial landscape has expanded significantly in recent years, driven by advances in immunotherapy, targeted therapy, and novel treatment modalities. Current areas of active investigation include combinations of immune checkpoint inhibitors (such as anti-PD-1 and anti-CTLA-4 antibodies), chimeric antigen receptor T-cell (CAR-T) therapy directed against mesothelin, tumor treating fields (TTFields) combined with chemotherapy, oncolytic viral therapy, and gene therapy approaches. These trials are conducted primarily at NCI-designated cancer centers with expertise in thoracic oncology.³

Participation in a clinical trial does not mean receiving unproven or unsafe treatment. All clinical trials in the United States are rigorously regulated by the FDA and overseen by institutional review boards (IRBs) that protect patient safety and rights. Patients in clinical trials receive at least the current standard of care — they are never given a placebo instead of effective treatment when a proven therapy exists. For mesothelioma patients, clinical trials offer access to cutting-edge therapies, close monitoring by specialized teams, and the opportunity to contribute to medical knowledge that may help future patients.¹

Current mesothelioma clinical trials span several major therapeutic categories, each exploring different mechanisms to combat this cancer:³

• Immunotherapy combinations — Building on the success of nivolumab plus ipilimumab (CheckMate 743), trials are evaluating new combinations of checkpoint inhibitors, including anti-PD-L1, anti-LAG-3, and anti-TIGIT antibodies. Some trials combine immunotherapy with chemotherapy, radiation, or targeted agents to enhance immune responses
• CAR-T cell therapy — Chimeric antigen receptor T-cell therapy engineers a patient's own immune cells to recognize and attack mesothelin, a protein highly expressed on mesothelioma cells. Several phase I/II trials are evaluating mesothelin-directed CAR-T cells delivered directly into the pleural space
• Tumor treating fields (TTFields) — Wearable devices that deliver low-intensity alternating electric fields to disrupt cancer cell division. The STELLAR trial demonstrated improved survival when TTFields were added to chemotherapy for pleural mesothelioma, and further studies are ongoing
• Oncolytic viral therapy — Genetically modified viruses that selectively infect and destroy cancer cells while stimulating anti-tumor immune responses. Trials are investigating intratumoral and intrapleural delivery of various oncolytic virus platforms
• Gene therapy — Approaches that deliver therapeutic genes (such as tumor suppressor genes like BAP1) directly to mesothelioma cells or modify the tumor microenvironment to enhance immune recognition
• Targeted therapy — Drugs targeting specific molecular pathways in mesothelioma, including EZH2 inhibitors (tazemetostat) for BAP1-deficient tumors, anti-angiogenic agents, and novel kinase inhibitors

Finding and enrolling in a mesothelioma clinical trial involves several steps:²

• Search ClinicalTrials.gov — The U.S. National Library of Medicine maintains a comprehensive database of all registered clinical trials at ClinicalTrials.gov. Search using terms like "mesothelioma" and filter by status (recruiting), phase, and location
• Contact NCI Cancer Information Service — The NCI's trained specialists (1-800-4-CANCER) can help identify appropriate trials based on your diagnosis, treatment history, and location
• Consult your oncologist — Your treating oncologist can review available trials, assess your eligibility based on medical criteria, and facilitate referrals to trial sites
• Review eligibility criteria — Each trial has specific inclusion and exclusion criteria related to cancer type, stage, prior treatments, organ function, and performance status. Not every patient will qualify for every trial
• Understand the protocol — Before enrolling, you will receive a detailed informed consent document explaining the trial's purpose, procedures, potential risks and benefits, alternatives, and your rights as a participant
• Travel and logistics — Many clinical trials are available only at specific cancer centers. Some trials and advocacy organizations offer travel assistance, lodging support, and financial aid programs for participants who need to travel⁴

Important: investigational treatments provided through clinical trials are typically supplied at no cost to the participant. However, routine care costs (standard tests, office visits) may be billed to insurance. Many insurers, including Medicare, are required by law to cover routine care costs associated with qualifying clinical trials.¹

Clinical trials have fundamentally shaped mesothelioma treatment and survival outcomes over the past two decades:³

• Standard of care advances — The cisplatin-pemetrexed chemotherapy regimen (approved 2004) and nivolumab-ipilimumab immunotherapy combination (approved 2020) both emerged from landmark clinical trials that demonstrated survival improvements over previous standards
• Survival improvements — Median survival for mesothelioma patients has gradually improved from approximately 9 months (with single-agent chemotherapy) to 14–18 months (with modern combination approaches), driven largely by clinical trial discoveries
• Access to innovation — Patients enrolled in clinical trials often gain access to promising new therapies years before they receive FDA approval and become widely available
• Safety record — Modern clinical trials have extensive safety monitoring, including Data Safety Monitoring Boards (DSMBs) that continuously review safety data and can halt a trial if unexpected risks emerge

Participating in a clinical trial involves practical considerations that patients and families should plan for:⁴

• Visit schedule — Clinical trials typically require more frequent office visits, imaging studies, and blood tests than standard treatment. Discuss the time commitment with the research team before enrolling
• Travel planning — If the trial site is distant from your home, ask about travel assistance programs, nearby lodging options, and whether some monitoring visits can be conducted at a local facility
• Communication with local oncologist — Ensure your local oncologist and the trial investigators communicate regularly about your care. Request copies of all trial-related test results for your personal medical records
• Your rights — You can withdraw from a clinical trial at any time for any reason without penalty. Your decision to leave a trial will not affect your access to standard cancer care
• Advocacy organizations — Groups such as the Mesothelioma Applied Research Foundation and the Asbestos Disease Awareness Organization can help connect patients with appropriate clinical trials and provide additional support resources